They studied the application of ADT in 35 patients with androgen receptor-positive advanced salivary duct carcinoma, which lead to a median overall survival (OS) of 17 months versus 5 months in 43 patients receiving best supportive care [34]. The gene discussed is AR; the disease is salivary duct carcinoma.